These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32526924)

  • 1. Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study.
    Pezzuto F; Serio G; Fortarezza F; Scattone A; Caporusso C; Punzi A; Cavone D; Pennella A; Marzullo A; Vimercati L
    Diagnostics (Basel); 2020 Jun; 10(6):. PubMed ID: 32526924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
    Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
    Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
    Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
    Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
    Dacic S; Kothmaier H; Land S; Shuai Y; Halbwedl I; Morbini P; Murer B; Comin C; Galateau-Salle F; Demirag F; Zeren H; Attanoos R; Gibbs A; Cagle P; Popper H
    Virchows Arch; 2008 Dec; 453(6):627-35. PubMed ID: 18958493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances.
    Geyer L; Wolf T; Chenard MP; Cebula H; Schott R; Noel G; Guerin E; Pencreach E; Reita D; Entz-Werlé N; Lhermitte B
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900302
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
    Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
    Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma.
    Jacobsen F; Kohsar J; Gebauer F; Kluth M; Hube-Magg C; Simon R; Bockhorn M; Hinsch A; Burandt E; Lübke AM; Steurer S; Tachezy M; Sauter G; Izbicki JR; Wilczak W; Melling N
    Oncotarget; 2020 Mar; 11(12):1007-1016. PubMed ID: 32256975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre.
    Marshall K; Jackson S; Jones J; Holme J; Lyons J; Barrett E; Taylor P; Bishop P; Hodgson C; Green M; Telford N; Evison M
    Lung Cancer; 2020 Dec; 150():195-200. PubMed ID: 33197684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletions of
    Vrugt B; Kirschner MB; Meerang M; Oehl K; Wagner U; Soltermann A; Moch H; Opitz I; Wild PJ
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894345
    [No Abstract]   [Full Text] [Related]  

  • 14. High Wilms' tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma.
    Scattone A; Serio G; Marzullo A; Nazzaro P; Corsi F; Cocca MP; Mattoni M; Punzi A; Gentile M; Buonadonna AL; Pennella A
    Histopathology; 2012 Feb; 60(3):472-81. PubMed ID: 22276610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of P16/CDKN2A deletion in pleural mesotheliomas.
    Ladanyi M
    Lung Cancer; 2005 Jul; 49 Suppl 1():S95-8. PubMed ID: 15950811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
    Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
    Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
    J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.
    Hwang H; Tse C; Rodriguez S; Gown A; Churg A
    Am J Surg Pathol; 2014 May; 38(5):681-8. PubMed ID: 24503757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
    López-Ríos F; Chuai S; Flores R; Shimizu S; Ohno T; Wakahara K; Illei PB; Hussain S; Krug L; Zakowski MF; Rusch V; Olshen AB; Ladanyi M
    Cancer Res; 2006 Mar; 66(6):2970-9. PubMed ID: 16540645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.